首页> 外文期刊>Annals of surgical oncology >Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer
【24h】

Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer

机译:MicroRNA-31-5p与转移性结直肠癌患者抗EGFR治疗的临床疗效的关系

获取原文
获取原文并翻译 | 示例

摘要

Gene mutations in the pathway downstream of epidermal growth factor receptor (EGFR) are considered to induce resistance to anti-EGFR therapy in colorectal cancer (CRC). We recently reported that microRNA-31 (miR-31)-5p may regulate BRAF activation and play a role in the signaling pathway downstream of EGFR in CRC. Therefore, we hypothesized that miR-31-5p can be a useful biomarker for anti-EGFR therapy in CRC.
机译:表皮生长因子受体(EGFR)下游通路中的基因突变被认为可诱导大肠癌(CRC)对抗EGFR治疗的耐药性。我们最近报道,microRNA-31(miR-31)-5p可能调节BRAF激活并在CRC的EGFR下游信号通路中发挥作用。因此,我们假设miR-31-5p可能是CRC中抗EGFR治疗的有用生物标志物。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号